Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Divalproex sodium is an anticonvulsant medication used primarily to treat seizure disorders (epilepsy), the manic phase of bipolar disorder, and to prevent migraine headaches. It is a stable coordination compound comprised of sodium valproate and valproic acid. The drug acts mainly by increasing brain levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that helps reduce excessive electrical activity in the brain. Additional mechanisms may include blockade of voltage-gated sodium channels and inhibition of histone deacetylase enzymes. Divalproex sodium is available only by prescription and comes in several oral dosage forms[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on divalproex sodium.